Aidoc vs PathAI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Aidoc employs 300 people, while PathAI has 300 employees.

Aidoc has raised more in total funding at $370M, compared to PathAI's $255M — a gap of $115M. Combined, the two companies have completed 11 known funding rounds.

Aidoc holds the higher Awaira Score at 67/100, compared to PathAI's 62/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 5-point gap that reflects meaningful differences in scale or traction.

Aidoc was founded by Elad Walach in 2016. PathAI was founded by Andy Beck in 2016. Visit each company's profile on Awaira for a full founder biography.

Aidoc: Aidoc is an Israeli artificial intelligence company founded in 2016 that develops clinical decision support software for radiology and medical imaging. The platform uses deep learning algorithms to analyze medical images, prioritize critical findings, and alert radiologists to potential abnormalities, particularly focusing on conditions requiring urgent intervention. Aidoc's core offering integrates into existing hospital workflows and PACS systems, enabling radiologists to identify and triage high-risk cases more efficiently. The company operates in the clinical AI segment, competing with firms like Zebra Medical Vision and Enlitic in automated imaging analysis. Aidoc's technology addresses the growing bottleneck of radiologist workload and diagnostic delays by automating preliminary image screening and flagging priority cases. The platform reportedly covers multiple pathologies including stroke, pulmonary embolism, and other acute conditions. As of the latest available data, Aidoc has secured $370 million in total funding through Series D stage, though its valuation remains not disclosed. The company has expanded internationally and serves healthcare institutions across multiple regions. Aidoc's growth trajectory reflects increasing institutional adoption of AI-assisted diagnostic tools in radiology departments globally, driven by workforce shortages and demand for faster diagnostic turnaround times in clinical settings. Aidoc focuses on clinical workflow integration rather than replacement, embedding AI directly into existing radiology infrastructure to accelerate diagnostic processes. PathAI: PathAI is an AI healthcare company founded in 2016 that develops digital pathology solutions and AI-powered diagnostic tools for pathology labs and healthcare institutions. The company specializes in machine learning algorithms designed to assist pathologists in analyzing tissue samples and identifying diseases, particularly cancer. PathAI's core technology platform leverages deep learning and computer vision to process histopathology images, enhancing diagnostic accuracy and workflow efficiency. The company's primary offering includes software that integrates with existing laboratory information systems, enabling pathologists to use AI-assisted analysis for specimen evaluation. PathAI has developed partnerships with major healthcare systems and diagnostic laboratories, demonstrating clinical utility in oncology and other pathology specialties. The platform addresses critical challenges in pathology including diagnostic consistency, workload management, and access to specialized expertise in underserved regions. PathAI has raised $255 million in total funding as of its Series C stage, with valuation not disclosed. The company operates in the competitive digital pathology and AI diagnostics space, alongside competitors offering similar computational pathology solutions. The digital pathology market is experiencing significant growth driven by increasing diagnostic demands, laboratory automation trends, and regulatory acceptance of AI-assisted tools. PathAI's trajectory reflects broader momentum in AI-enabled healthcare diagnostics and precision medicine applications. PathAI combines deep learning with pathology workflows to create clinically integrated AI tools that assist rather than replace human pathologists.

Both Aidoc and PathAI were founded in the same year — 2016. Despite sharing a founding year, they may have launched at different times within that year, which can matter in fast-moving AI markets.

Both Aidoc and PathAI report similar employee counts of approximately 300. Team size is often a proxy for operational scale, though lean AI companies can punch well above their headcount.

Yes, Aidoc and PathAI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.